[Screening of exocrine pancreatic function (author's transl)].
The validity of oral pancreatic function tests (fluoresceine dilaurate-[FDL-], N-benzoyl-L-tyrosyl-para-amino-benzoic-acid-[PABA-]test) was assessed intra-individually in 67 patients in comparison with the secretin-pancreozymin test corrected for volume loss. Faecal chymotrypsin (CH-F) estimation was included in the comparison. According to the result of the secretin-pancreozymin test, patients were divided into those with normal pancreatic function (n = 28), those with borderline restricted function (n = 18), and those with manifest exocrine insufficiency (n = 21). Results show that in borderline decreased pancreatic function the diagnostic value of all screening tests is limited. The sensitivity (true pathological results) was 38% in the FDL-test, 40% in the PABA-test, and 31% in CH-F. In manifest exocrine pancreatic insufficiency FDL- and PABA-test as well as CH-F showed similar sensitivity of 67, 63, and 62%, respectively. Results show that oral pancreatic function tests, particularly the simple FDL-test, represent a diagnostic alternative to the relatively complicated CH-F assessment. However, none of the tests are able to replace the secretin-pancreozymin test as the most valid diagnostic investigation.
D010129:4-Aminobenzoic Acid; D000328:Adult; D000368:Aged; D002766:Cholecystokinin; D002918:Chymotrypsin / Q000032:analysis; D010188:Exocrine Pancreatic Insufficiency / Q000175:diagnosis; D005243:Feces / Q000201:enzymology; D005260:Female; D005452:Fluoresceins; D006801:Humans; D008297:Male; D008875:Middle Aged; D010186:Pancreatic Function Tests; D012633:Secretin
D005452:Fluoresceins; D012633:Secretin; D002766:Cholecystokinin; D002918:Chymotrypsin; D010129:4-Aminobenzoic Acid
Funktions-"Screening" des exokrinen Pankreas. FDL-, N-BT-PABA-Test, Stuhl-Chymotrypsinbestimmung im Vergleich mit dem Sekretin-Pankreozymin-Test.